FDA Approves Leucovorin for Autism Symptoms Amid Expert Caution
The FDA has approved leucovorin for treating autism symptoms associated with cerebral folate deficiency, prompting both hope and calls for further research.
The U.S. Food and Drug Administration (FDA) has approved leucovorin calcium tablets for patients with cerebral folate deficiency (CFD), a neurological condition linked to autism spectrum disorders.
Leucovorin, also known as folinic acid, is a derivative of vitamin B traditionally used to mitigate side effects of certain chemotherapy drugs. Its approval for CFD is based on a systematic analysis of literature published between 2009 and 2024, which suggests potential benefits for individuals with this condition.
FDA Commissioner Marty Makary stated, "We have witnessed a tragic four-fold increase in autism over two decades. Children are suffering and deserve access to potential treatments that have shown promise."
However, some health experts express caution. Danielle Hall, director of health equity at the Autism Society of America, noted that current studies on high-dose leucovorin are very preliminary. She warned that premature claims about its efficacy could lead to false hope and misinterpretation that leucovorin represents a cure.
The FDA is collaborating with GlaxoSmithKline (GSK), the manufacturer of Wellcovorin (leucovorin calcium), to update the drug's labeling to include its new indication for CFD.
While some studies have shown improvements in language abilities among children with autism treated with leucovorin, experts emphasize the need for larger, rigorous trials to confirm these findings.
The FDA's decision marks a significant step in addressing autism-related conditions, but health professionals urge continued research to fully understand the drug's efficacy and safety in this new context.